Abstract
BACKGROUND: Scientific advancements have increased the use of biomarker testing for metastatic breast cancer (mBC) treatment decisions, adding complexity which may impact patient understanding. This study assesses patient recall and understanding of biomarker information and barriers to understanding diagnosis. MATERIALS AND METHODS: An online, multi-language, 15-question multiple choice survey was distributed to people with a self-reported diagnosis of mBC through the Advanced Breast Cancer (ABC) Global Alliance. Data collected included patient demographics, disease history, information seeking behaviour, and barriers to learning about their breast cancer subtype. RESULTS: Across 36 countries, 1064 respondents completed the survey. 81% recognised that their breast cancer subtype influences treatment decisions, though there was wide variation in patient recall of terminology used by their healthcare professionals (HCPs). Recall of the term 'biomarker' was low (8%). Geographical differences existed in patient recall of specific biomarkers used to describe mBC diagnosis; 'hormone receptor-positive (HR+)' recall was significantly higher for patients from North America (73%), compared with other regions (14%-56%). One-third (33%) of patients did not understand their breast cancer subtype and what it means. Only 44% of patients felt HCPs had given them sufficient information about their breast cancer subtype. A subset of patients (7%) reported not wanting to learn more, with the highest proportion from Latin America (17%). CONCLUSIONS: Findings demonstrate limited patient recall and understanding of breast cancer biomarkers and subtype, with significant variation based on geography. Results may be used to improve two-way communication and patient understanding regarding biomarker status, to facilitate shared decision-making.